Literature DB >> 15540205

CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells.

Margitta M Retz1, Sukhvinder S Sidhu, Ekaterina Blaveri, Sheena C Kerr, Gregory M Dolganov, Jan Lehmann, Peter Carroll, Jeff Simko, Frederic M Waldman, Carol Basbaum.   

Abstract

Transitional cell carcinoma of the urinary bladder remains life threatening due to the high occurrence of metastases. Emerging evidence suggests that chemokines and their receptors play a critical role in tumor metastases. In our study, we performed a systematic analysis of the mRNA and protein expression levels of all 18 chemokine receptors in normal urothelium and bladder cancer. CXCR4 was the only chemokine receptor whose mRNA expression level was upregulated in bladder cancer cell lines as well as in invasive and locally advanced bladder cancer tissue samples (pT2-pT4). In contrast, superficial bladder tumors (pTa and pT1) displayed low CXCR4 expression levels and normal urothelial cells were negative for CXCR4. Immunohistochemistry of a bladder cancer tissue microarray (TMA) confirmed that a subgroup of invasive bladder cancers revealed a high CXCR4 protein expression, while superficial bladder tumors showed low immunoreactivity. To investigate the functional significance of CXCR4 expression, we performed migration and invasion assays. Exposure of CXCR4-positive bladder cancer cells to CXCL12 in a Boyden chamber type assay provoked a significant increase in migration as well as invasion across a Matrigel barrier. Enhanced migration and invasion were inhibited by a CXCR4-specific blocking antibody. In contrast, normal urothelial cells did not respond to CXCL12 and lacked chemotactic migration. In conclusion, bladder cancer cells express CXCR4 progressively with advanced tumorigenesis and this receptor interacts with CXCL12 to mediate tumor chemotaxis and invasion through connective tissue. These properties identify CXCR4 as a potential target for the attenuation of bladder cancer metastases. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15540205     DOI: 10.1002/ijc.20729

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  [Bladder cancer--what's new].

Authors:  J Gschwend
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

2.  C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer.

Authors:  Travis J Yates; Judith Knapp; Miguel Gosalbez; Soum D Lokeshwar; Christopher S Gomez; Anaid Benitez; Obi O Ekwenna; Ezekiel E Young; Murugesan Manoharan; Vinata B Lokeshwar
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis.

Authors:  Cheng-Liang Yang; Shun-Shou Liu; Ye-Gang Ma; Yong-Yu Liu; Yi-Xue Xue; Bo Huang
Journal:  Med Oncol       Date:  2011-02-11       Impact factor: 3.064

4.  Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer.

Authors:  Jun Taik Lee; Sang Don Lee; Jeong Zoo Lee; Moon Kee Chung; Hong Koo Ha
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

5.  CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer.

Authors:  Hai-bo Shen; Zheng-qin Gu; Kang Jian; Juan Qi
Journal:  Tumour Biol       Date:  2013-03-23

6.  Differential expression of SDF-1 isoforms in bladder cancer.

Authors:  Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

Review 7.  HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.

Authors:  Elizabeth M Gaughan; Bruce J Dezube; Mark Bower; David M Aboulafia; Gerry Bohac; Timothy P Cooley; Liron Pantanowitz
Journal:  BMC Urol       Date:  2009-08-31       Impact factor: 2.264

8.  Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma.

Authors:  Thilo Welsch; Shereen Keleg; Frank Bergmann; Luca Degrate; Sonja Bauer; Jan Schmidt
Journal:  Clin Exp Metastasis       Date:  2009-06-02       Impact factor: 5.150

Review 9.  [How do metastases of urological tumors develop?].

Authors:  M Rose; R Knüchel
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

Review 10.  Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.

Authors:  Alireza Nazari; Hossein Khorramdelazad; Gholamhossein Hassanshahi
Journal:  Int J Clin Oncol       Date:  2017-10-11       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.